Precigen, Inc. (NASDAQ:PGEN) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET

Company Participants

Steven Harasym - VP, IR
Helen Sabzevari - President & CEO
Harry Thomasian - CFO
Phil Tennant - Chief Commercial Officer
Rutul Shah - COO

Conference Call Participants

Carolina Ibanez Ventoso - Stifel
Jason Butler - Citizens JMP
Swayampakula Ramakanth - H.C. Wainwright
Jennifer Kim - Cantor Fitzgerald

Operator

Good evening and welcome to the Precigen’s Second Quarter and First Half 2024 Financial Results Call. At this time, all lines are in a listen-only mode. Following the presentation, there will be a question-and-answer session. [Operator Instructions]

Please note, this event is being recorded. I would now like to turn the conference over to Steve Harasym, Vice President of Investor Relations. Please go ahead.

Steven Harasym

Thank you, Jenny, and thank you for everyone joining us this afternoon. With me today are Dr. Helen Sabzevari, President and CEO of Precigen; Harry Thomasian, our CFO; Phil Tennant, our Chief Commercial Officer, and our Chief Operating Officer, Rutul Shah.

Before we begin, let me briefly review our forward-looking statements. During today's call, we will make various forward-looking statements. Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated by forward-looking statements.

Please read the Safe Harbor Statement contained in our most recent SEC filings, as well as risk factors contained in Precigen’s filings.

With that, I would like to now turn the call over to Dr. Sabzevari. Helen?

Helen Sabzevari

Thank you, Steve, And thank you to all joining us today. It is a pivotal time at Precigen, as we work hard to get what could be the first FDA approved treatment for the devastating recurrent respiratory papillomatosis disease, or as we know it, RRP, to the market. What I would like to do at the beginning is take you through some of the key programs and business highlights and then go through some of the strategic prioritization that has been communicated recently.

Let me start by talking about PRGN-2012, which is the focus now of our portfolio. As you know, PRGN-2012 is our adenovirus gene therapy, that is designed to elicit immune responses directed to HPV6 and HPV11, infected tumors and to raise the immune system to both of these epitopes, both HPV6 and HPV11, for the treatment of recurrent respiratory papillomatosis.